Boehringer partners with Chinese university for infectious disease therapies

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Tsinghua University (Beijing, China) partnered to research and develop therapies for infectious diseases using immune modulation.

The Tsinghua deal is part of Boehringer's Research Beyond Borders (RBB) program, designed to incubate promising technologies that could complement the company's core therapeutic areas, but do not yet fit into any of its ongoing programs. The company said immuno-infection is a new focus for its RBB department...